Madrigal Pharmaceuticals Net Worth
Madrigal Pharmaceuticals Net Worth Breakdown | MDGL |
Madrigal Pharmaceuticals Net Worth Analysis
Madrigal Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Madrigal Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Madrigal Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Madrigal Pharmaceuticals' net worth analysis. One common approach is to calculate Madrigal Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Madrigal Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Madrigal Pharmaceuticals' net worth. This approach calculates the present value of Madrigal Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Madrigal Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Madrigal Pharmaceuticals' net worth. This involves comparing Madrigal Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Madrigal Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Madrigal Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Madrigal Pharmaceuticals' net worth research are outlined below:
| Madrigal Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 180.13 M. Net Loss for the year was (465.89 M) with profit before overhead, payroll, taxes, and interest of 173.9 M. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (455.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Madrigal Pharmaceuticals Among the Best Biotech Stocks to Buy According to Billionaires |
Madrigal Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Madrigal Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Madrigal Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Madrigal Pharmaceuticals Target Price Consensus
Madrigal target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Madrigal Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Strong Buy |
Most Madrigal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Madrigal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Madrigal Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMadrigal Pharmaceuticals Target Price Projection
Madrigal Pharmaceuticals' current and average target prices are 335.13 and 373.00, respectively. The current price of Madrigal Pharmaceuticals is the price at which Madrigal Pharmaceuticals is currently trading. On the other hand, Madrigal Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Madrigal Pharmaceuticals Market Quote on 20th of March 2025
Target Price
Analyst Consensus On Madrigal Pharmaceuticals Target Price
Know Madrigal Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Madrigal Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Madrigal Pharmaceuticals backward and forwards among themselves. Madrigal Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Madrigal Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| William Blair Investment Management, Llc | 2024-12-31 | 371.8 K | |
| Ubs Group Ag | 2024-12-31 | 325.3 K | |
| Woodline Partners Lp | 2024-12-31 | 309.1 K | |
| Rock Springs Capital Management Lp | 2024-12-31 | 265.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 231.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 218.5 K | |
| Bank Of America Corp | 2024-12-31 | 217.8 K | |
| Pictet Asset Manangement Sa | 2024-12-31 | 208.5 K | |
| Artisan Partners Limited Partnership | 2024-12-31 | 207.5 K | |
| Hhg Plc | 2024-12-31 | 2.2 M | |
| Paulson & Company Inc | 2024-12-31 | 2 M |
Follow Madrigal Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.52 B.Market Cap |
|
Project Madrigal Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.62) | (0.59) |
When accessing Madrigal Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Madrigal Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Madrigal Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Madrigal Pharmaceuticals' management efficiency
Madrigal Pharmaceuticals has return on total asset (ROA) of (0.3698) % which means that it has lost $0.3698 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8035) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.47. The value of Return On Capital Employed is expected to slide to -0.6. At this time, Madrigal Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 35.46 | 49.87 | |
| Tangible Book Value Per Share | 35.24 | 49.86 | |
| Enterprise Value Over EBITDA | (14.36) | (15.08) | |
| Price Book Value Ratio | 8.70 | 9.14 | |
| Enterprise Value Multiple | (14.36) | (15.08) | |
| Price Fair Value | 8.70 | 9.14 | |
| Enterprise Value | 6.5 B | 6.8 B |
At Madrigal Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Madrigal Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Madrigal Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Madrigal Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Madrigal Pharmaceuticals Corporate Filings
F4 | 14th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 12th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Madrigal Pharmaceuticals Earnings Estimation Breakdown
The calculation of Madrigal Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Madrigal Pharmaceuticals is estimated to be -6.28 with the future projection ranging from a low of -5.0436 to a high of -2.71. Please be aware that this consensus of annual earnings estimates for Madrigal Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-5.04 Lowest | Expected EPS | -2.71 Highest |
Madrigal Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Madrigal Pharmaceuticals' value are higher than the current market price of the Madrigal Pharmaceuticals stock. In this case, investors may conclude that Madrigal Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Madrigal Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 16 | 84.43% | -2.71 | -6.28 | -21.91 |
Madrigal Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Madrigal Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Madrigal Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Madrigal Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Madrigal Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Madrigal Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Madrigal Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Madrigal Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Madrigal Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -4.1246 | -2.71 | 1.4146 | 34 | ||
2024-10-31 | 2024-09-30 | -6.91 | -4.92 | 1.99 | 28 | ||
2024-08-07 | 2024-06-30 | -7.53 | -7.1 | 0.43 | 5 | ||
2024-05-07 | 2024-03-31 | -6.28 | -7.38 | -1.1 | 17 | ||
2024-02-28 | 2023-12-31 | -5.28 | -5.68 | -0.4 | 7 | ||
2023-11-06 | 2023-09-30 | -4.93 | -5.34 | -0.41 | 8 | ||
2023-08-08 | 2023-06-30 | -4.58 | -4.69 | -0.11 | 2 | ||
2023-05-09 | 2023-03-31 | -4.94 | -4.23 | 0.71 | 14 | ||
2023-02-23 | 2022-12-31 | -4.56 | -4.98 | -0.42 | 9 | ||
2022-11-03 | 2022-09-30 | -4.15 | -4.75 | -0.6 | 14 | ||
2022-08-04 | 2022-06-30 | -3.7 | -4.14 | -0.44 | 11 | ||
2022-05-09 | 2022-03-31 | -3.62 | -3.36 | 0.26 | 7 | ||
2022-02-24 | 2021-12-31 | -3.88 | -3.78 | 0.1 | 2 | ||
2021-11-04 | 2021-09-30 | -3.9 | -3.79 | 0.11 | 2 | ||
2021-08-05 | 2021-06-30 | -3.58 | -3.72 | -0.14 | 3 | ||
2021-05-06 | 2021-03-31 | -3.84 | -3.32 | 0.52 | 13 | ||
2021-02-25 | 2020-12-31 | -3.85 | -3.82 | 0.03 | 0 | ||
2020-11-05 | 2020-09-30 | -3.3 | -3.75 | -0.45 | 13 | ||
2020-08-06 | 2020-06-30 | -2.45 | -3.18 | -0.73 | 29 | ||
2020-05-07 | 2020-03-31 | -1.94 | -2.34 | -0.4 | 20 | ||
2020-02-26 | 2019-12-31 | -1.65 | -1.8 | -0.15 | 9 | ||
2019-11-06 | 2019-09-30 | -1.52 | -1.39 | 0.13 | 8 | ||
2019-08-07 | 2019-06-30 | -1.2 | -1.28 | -0.08 | 6 | ||
2019-05-08 | 2019-03-31 | -0.97 | -0.98 | -0.01 | 1 | ||
2019-02-27 | 2018-12-31 | -0.74 | -0.75 | -0.01 | 1 | ||
2018-11-06 | 2018-09-30 | -0.53 | -0.56 | -0.03 | 5 | ||
2018-08-07 | 2018-06-30 | -0.63 | -0.45 | 0.18 | 28 | ||
2018-05-08 | 2018-03-31 | -0.78 | -0.45 | 0.33 | 42 | ||
2018-03-13 | 2017-12-31 | -0.7 | -0.67 | 0.03 | 4 | ||
2017-11-09 | 2017-09-30 | -0.79 | -0.68 | 0.11 | 13 | ||
2017-08-10 | 2017-06-30 | -0.6 | -0.69 | -0.09 | 15 | ||
2017-05-11 | 2017-03-31 | -0.87 | -0.5 | 0.37 | 42 | ||
2017-03-31 | 2016-12-31 | -1.39 | -0.67 | 0.72 | 51 | ||
2016-11-14 | 2016-09-30 | -0.35 | -1.59 | -1.24 | 354 | ||
2016-07-20 | 2016-06-30 | -0.7 | -0.7 | 0.0 | 0 | ||
2016-05-10 | 2016-03-31 | -1.05 | -1.75 | -0.7 | 66 | ||
2016-03-15 | 2015-12-31 | -5.6 | -2.8 | 2.8 | 50 | ||
2015-11-05 | 2015-09-30 | -5.6 | -4.55 | 1.05 | 18 | ||
2015-08-06 | 2015-06-30 | -6.36 | -5.25 | 1.11 | 17 | ||
2015-05-07 | 2015-03-31 | -6.87 | -6.65 | 0.22 | 3 | ||
2015-03-12 | 2014-12-31 | -7.28 | -6.65 | 0.63 | 8 | ||
2014-11-06 | 2014-09-30 | -8.46 | -6.65 | 1.81 | 21 | ||
2014-08-06 | 2014-06-30 | -9.33 | -8.4 | 0.93 | 9 | ||
2014-05-08 | 2014-03-31 | -10.03 | -9.8 | 0.23 | 2 | ||
2014-03-11 | 2013-12-31 | -10.5 | -10.85 | -0.35 | 3 | ||
2013-11-04 | 2013-09-30 | -10.72 | -11.55 | -0.83 | 7 | ||
2013-08-01 | 2013-06-30 | -10.32 | -11.55 | -1.23 | 11 | ||
2013-04-30 | 2013-03-31 | -9.36 | -10.5 | -1.14 | 12 | ||
2013-03-14 | 2012-12-31 | -9.15 | -10.15 | -1.0 | 10 | ||
2012-11-06 | 2012-09-30 | -8.28 | -8.75 | -0.47 | 5 | ||
2012-08-02 | 2012-06-30 | -9.3 | -8.75 | 0.55 | 5 | ||
2012-05-03 | 2012-03-31 | -8.63 | -9.45 | -0.82 | 9 | ||
2012-02-22 | 2011-12-31 | -9.35 | -7.7 | 1.65 | 17 | ||
2011-11-03 | 2011-09-30 | -9.97 | -10.5 | -0.53 | 5 | ||
2011-08-04 | 2011-06-30 | -6.79 | -10.5 | -3.71 | 54 | ||
2011-05-05 | 2011-03-31 | -9.74 | -9.45 | 0.29 | 2 | ||
2010-11-04 | 2010-09-30 | -7.7 | -8.75 | -1.05 | 13 | ||
2010-08-09 | 2010-06-30 | -8.05 | -7.7 | 0.35 | 4 | ||
2010-05-04 | 2010-03-31 | -7.35 | -8.4 | -1.05 | 14 | ||
2010-03-11 | 2009-12-31 | -8.61 | -7.35 | 1.26 | 14 | ||
2009-11-04 | 2009-09-30 | 61.25 | 121.8 | 60.55 | 98 | ||
2009-08-04 | 2009-06-30 | -11.72 | -8.75 | 2.97 | 25 | ||
2009-05-07 | 2009-03-31 | -18.78 | -24.15 | -5.37 | 28 | ||
2009-03-26 | 2008-12-31 | -30.73 | -26.95 | 3.78 | 12 | ||
2008-11-13 | 2008-09-30 | -23.05 | -27.3 | -4.25 | 18 | ||
2008-08-07 | 2008-06-30 | -20.25 | -23.45 | -3.2 | 15 | ||
2008-05-14 | 2008-03-31 | -18.11 | -18.2 | -0.09 | 0 | ||
2008-03-20 | 2007-12-31 | -17.64 | -16.1 | 1.54 | 8 | ||
2007-11-13 | 2007-09-30 | -20.07 | -15.75 | 4.32 | 21 | ||
2007-08-06 | 2007-06-30 | -18.43 | -17.5 | 0.93 | 5 | ||
2007-05-07 | 2007-03-31 | -17.03 | -19.95 | -2.92 | 17 |
Madrigal Pharmaceuticals Corporate Management
| Justin Drinkwine | Senior VP | Profile | |
| Thomas Hare | Senior Management | Profile | |
| Remy Sukhija | VP Officer | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Mark Underwood | Senior Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.